Article
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
The lancet. Gastroenterology & hepatology - 1 Nov 2017
Gane Edward J, Pianko Stephen, Roberts Stuart K, Thompson Alexander J, Zeuzem Stefan, Zuckerman Eli, Ben-Ari Ziv, Foster Graham R, Agarwal Kosh, Laursen Alex L, Gerstoft Jan, Gao Wei, Huang Hsueh-Cheng, Fitzgerald Brian, Fernsler Doreen, Li Jerry J, Grandhi Anjana, Liu Hong, Su Feng-Hsiu, Wan Shuyan, Zeng Zhen, Chen Huei-Ling, Dutko Frank J, Nguyen Bach-Yen T, Wahl Janice, Robertson Michael N, Barr Eliav, Yeh Wendy W, Plank Rebeca M, Butterton Joan R, Esteban Rafael
Abstract excerpt
BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.